Loading…
Boundless Bio, Inc. is projected to rise to $2.75 by 2027, a +14% move from its current price of $2.41. BOLD is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $2.34 | $2.41 | $2.48 | -0.01% |
| Jul 13 | $2.31 | $2.41 | $2.51 | -0.01% |
| Jul 14 | $2.29 | $2.41 | $2.53 | -0.02% |
| Jul 15 | $2.27 | $2.41 | $2.55 | -0.02% |
| Jul 16 | $2.26 | $2.41 | $2.57 | -0.03% |
| Jul 17 | $2.24 | $2.41 | $2.59 | -0.03% |
| Jul 18 | $2.23 | $2.41 | $2.60 | -0.04% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.23 | $2.41 | $2.60 | -0.04% |
| Week 2 | $2.16 | $2.41 | $2.68 | -0.07% |
| Week 3 | $2.11 | $2.41 | $2.75 | -0.11% |
| Week 4 | $2.06 | $2.41 | $2.81 | -0.14% |
| Week 5 | $2.03 | $2.41 | $2.86 | -0.18% |
| Week 6 | $1.99 | $2.40 | $2.90 | -0.22% |
| Week 7 | $1.96 | $2.40 | $2.94 | -0.25% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Boundless Bio, Inc. is a clinical-stage oncology company focused on developing interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype.
The company was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. Boundless Bio, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Boundless Bio, Inc. (BOLD) is currently priced at $2.41 and trades with a market cap of $54.16M, ranking 4491. The current price and market position place it among smaller-cap healthcare stocks with a focused oncology program.
Forecasts show potential upside over the coming years, with 2026 projecting an avg price of $2.41 (ROI 0%) and a bullish path developing toward higher prices in subsequent years. The 2027 avg is $2.75, the 2028 avg is $3.01, and the 2030 avg is $3.00, culminating in a long-run outlook that includes $7.00 by 2040 and $13.04 by 2050.
A major floor 62.2% below — a decisive break under it would weaken the trend.
The nearest floor, 42.7% below — buyers have tended to step in here.
The nearest ceiling, 7.9% above — a clean break opens room to run.
A major ceiling 39.0% above — clearing it would confirm fresh momentum.
Key BOLD support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BOLD market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.47 | Sell | $2.46 | Sell |
| MA 10 | $2.49 | Sell | $2.40 | Buy |
| MA 20 | $2.12 | Buy | $2.20 | Buy |
| MA 50 | $1.73 | Buy | $1.85 | Buy |
| MA 100 | $1.48 | Buy | $1.62 | Buy |
| MA 200 | $1.35 | Buy | $1.56 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 67.32 | Neutral |
| Stoch RSI (14) | 50.01 | Neutral |
| CCI (20) | 38.57 | Neutral |
| Williams %R (14) | -15.83 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | -7.31 | Sell |
| Bollinger %B (20,2) | 0.64 | Neutral |
| Stochastic %K (14) | 84.17 | Sell |
| TRIX (15) | 2.19 | Buy |
| Awesome (5,34) | 0.63 | Buy |
| Ultimate (7,14,28) | 50.94 | Neutral |
| Momentum (10) | -0.10 | Sell |
| Aroon Osc (25) | 36.00 | Buy |
| Hull MA (9) | 2.46 | Sell |
| ADX (14) | 37.27 | Buy |
| ATR (14) | 0.07 | Info |
The 30-day technical picture is bullish with RSI(14) at 70. The stock trades with a resistance at $2.60 and a support at $1.38, reflecting a measured upside against a bullish bias.
The 50-day simple moving average sits at $1.73, while the 200-day simple moving average is $1.35, signaling potential upside if price action continues to trend higher.
Over the last 30 days, the price ranged from a low of $1.99 to a high of $2.92, indicating a constructive near-term trading range and room for movement toward the nearby resistance as momentum remains positive.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.05 | $2.41 | $3.15 | 0% | Neutral | |
| $2.18 | $2.75 | $3.68 | +14% | Neutral | |
| $2.31 | $3.01 | $4.19 | +25% | Bullish | |
| $2.07 | $2.76 | $3.96 | +15% | Neutral | |
| $2.20 | $3.00 | $4.41 | +24% | Bullish | |
| $2.65 | $3.68 | $5.55 | +53% | Bullish | |
| $2.89 | $4.10 | $6.30 | +70% | Bullish | |
| $3.17 | $4.58 | $7.16 | +90% | Bullish | |
| $3.13 | $4.60 | $7.31 | +91% | Bullish | |
| $3.01 | $4.49 | $7.25 | +86% | Bullish | |
| $4.37 | $7.00 | $12.05 | +190% | Bullish | |
| $7.17 | $13.04 | $24.66 | +441% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.05 | $2.41 | $2.92 | +0.00% |
| August 2026 | $2.03 | $2.39 | $2.91 | -0.63% |
| September 2026 | $2.01 | $2.40 | $2.95 | +0.16% |
| October 2026 | $2.08 | $2.49 | $3.09 | +3.87% |
| November 2026 | $2.08 | $2.51 | $3.15 | +0.80% |
| December 2026 | $2.06 | $2.50 | $3.15 | -0.58% |
Click any year to see its month-by-month BOLD forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect BOLD to range from $1.05 to $3.15 through 2026. The $2.41 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The BOLD price prediction for 2027 points to an average of $2.75 (low $2.18, high $3.68) — a potential gain of +14% on today's $2.41. A consolidation phase looks the most probable path here.
In 2028, BOLD is projected to trade between $2.31 and $4.19, averaging $3.01 — a potential gain of +25% from today's $2.41. That is up +9% on the projected 2027 average. Momentum favours further upside here.
Boundless Bio, Inc.'s 2029 outlook centres on $2.76, within a $2.07 to $3.96 range. That is -8% versus the projected 2028 average. That marks a +15% change versus current levels. A consolidation phase looks the most probable path here.
By 2030, BOLD could reach as high as $4.41, with a base case around $3.00 and support toward $2.20 — roughly +24% from $2.41. Momentum favours further upside here.
Expect BOLD to range from $2.65 to $5.55 through 2031. The $3.68 average target implies a +53% move from current prices. That is up +23% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The BOLD price prediction for 2032 points to an average of $4.10 (low $2.89, high $6.30) — a potential gain of +70% on today's $2.41. Momentum favours further upside here.
In 2033, BOLD is projected to trade between $3.17 and $7.16, averaging $4.58 — a potential gain of +90% from today's $2.41. That is up +12% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Boundless Bio, Inc.'s 2034 outlook centres on $4.60, within a $3.13 to $7.31 range. That is up 0% on the projected 2033 average. That marks a +91% change versus current levels. Momentum favours further upside here.
By 2035, BOLD could reach as high as $7.25, with a base case around $4.49 and support toward $3.01 — roughly +86% from $2.41. Buyers look set to stay in control over this stretch.
Expect BOLD to range from $4.37 to $12.05 through 2040. The $7.00 average target implies a +190% move from current prices. That is up +56% on the projected 2035 average. Momentum favours further upside here.
The BOLD price prediction for 2050 points to an average of $13.04 (low $7.17, high $24.66) — a potential gain of +441% on today's $2.41. Buyers look set to stay in control over this stretch.
Investing $1,000 in BOLD today (≈ 414.937759 BOLD) could be worth
$5,411.09
+$4,411.09 (+441%) by 2050 · US Dollar
Based on the average projected BOLD price of $13.04 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BOLDwould be worth at today's price.
$1,000 invested in BOLD on Jul 10, 2025 (≈ 847.457665 BOLD) would be worth
$2,042.37
+$1,042.37 (+104.2%) today · 2.04× · US Dollar
Based on a BOLD entry price of $1.18 vs. today's $2.41.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.5 | $964 | -3.6% |
| 1 month ago | $1.38 | $1,746.38 | +74.6% |
| 3 months ago | $1.13 | $2,132.74 | +113.3% |
| 6 months ago | $1.24 | $1,943.55 | +94.4% |
| 1 year ago | $1.18 | $2,042.37 | +104.2% |
| All time (2.3y) ago | $14.25 | $169.12 | -83.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BOLD forecast.
Our base-case forecast reaches $4.80 around 2040.
Implied market cap at $4.80: $107.88M
The multi-year forecast shows meaningful upside, with the 2030 avg price at $3.00 and a 24.4% ROI, and the 2040 avg price at $7.00 with a 190.3% ROI. The 2050 forecast projects an avg of $13.04 and a 441.1% ROI, underscoring a long-run bullish trajectory if the trajectory holds.
Key intermediate milestones include 2027 avg $2.75 (ROI 14.2%) and 2028 avg $3.01 (ROI 24.8%), followed by continued bullish sentiment through 2031–2035. The 2031 avg is $3.68 and the 2032 avg is $4.10, with 2033–2035 remaining bullish at progressively higher levels. While the outlook shows strong upside potential, these are estimates and not guarantees, and actual results will depend on a range of factors beyond these figures.
Tap a question to reveal the answer.
2030 avg $3.00, min $2.20, max $4.41, ROI 24.4%, sentiment BULLISH.
Forecasts show potential upside in several years (e.g., 2031–2050) with avg prices higher than the current level, and 2026 shows ROI of 0%. These figures are estimates and not guarantees.
Yes, the 2040 max price is $12.05; the 2040 avg is $7.00 and the 2040 ROI is 190.3%.
Current price is $2.41 and market cap is $54.16M.
2028 avg $3.01, min $2.31, max $4.19, ROI 24.8%, sentiment BULLISH.
Boundless Bio, Inc. Community Discussion
0Share your Boundless Bio, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.